Skip to main content

Genetimes Distributing NanoInk Products in China

NEW YORK (GenomeWeb News) – NanoInk today announced a non-exclusive deal with Genetimes Technology for the distribution of NanoInk's products in China.

Under the terms of the deal, Genetimes will distribute the Skokie, Ill.-based company's desktop nanofabrication equipment, including the NLP 2000 System and DPN 5000 System. Further details of the deal were not disclosed.

According to Oliver Yeh, general manager of NanoInk's NanoFabrication Systems Division, Asia-Pacific region, Genetimes has offices in 12 cities as well as strong relationships with NanoInk's target customers, making it "the ideal partner for driving sales of NanoInk's unique nanofabrication platforms for use in life science and bioengineering applications."

Genetimes is based in Shanghai and provides products and services for life science research, including next-generation sequencing, molecular biology, immunology, cell biology, stem cell research, and other applications.

Today's announcement is the third from NanoInk in the past year covering distribution deals in Asia. In the fall it signed on E-Hong to distribute its products in Taiwan, and last May it announced a non-exclusive agreement with the Research Institute of Biomolecule Metrology for distribution of its products in Japan.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.